Out-of-Pocket Spending for Biologic Drugs After Biosimilar Competition for Medicare Patients.
Saved in:
| Title: | Out-of-Pocket Spending for Biologic Drugs After Biosimilar Competition for Medicare Patients. |
|---|---|
| Authors: | Riegler JS; Program On Regulation, Therapeutics, And Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.; Department of Medicine, Cambridge Health Alliance, Cambridge, Massachusetts.; Harvard Business School, Boston, Massachusetts., Kesselheim AS; Program On Regulation, Therapeutics, And Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts., Rome BN; Program On Regulation, Therapeutics, And Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts. |
| Source: | JAMA network open [JAMA Netw Open] 2026 Jan 02; Vol. 9 (1), pp. e2554235. Date of Electronic Publication: 2026 Jan 02. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: American Medical Association Country of Publication: United States NLM ID: 101729235 Publication Model: Electronic Cited Medium: Internet ISSN: 2574-3805 (Electronic) Linking ISSN: 25743805 NLM ISO Abbreviation: JAMA Netw Open Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
